Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors-Reference-Cited by-同舟云学术

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors

Published:2017-09-25 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Chai-Adisaksopha Chatree¹,Nevitt Sarah J²,Simpson Mindy L³,Janbain Maissaa⁴,Konkle Barbara A⁵

Affiliation:

1. McMaster University; Hamilton Ontario Canada

2. University of Liverpool; Department of Biostatistics; Block F, Waterhouse Building 1-5 Brownlow Hill Liverpool UK L69 3GL

3. Rush University Medical Center; Section of Pediatric Hematology/Oncology; 1653 W Congress Parkway Chicago USA IL 60612

4. Tulane University School of Medicine; Department of Hematology & Medical Oncology; 1430 Tulane Avenue New Orleans Louisiana USA LA 70112

5. 921 Terry Avenue; Bloodworks North West; Seattle Washington USA WA 98104

Publisher

Wiley

Subject

Pharmacology (medical)

Reference63 articles.

1. A prospective, open-label, randomized, parallel study with AICC to evaluate the efficacy and safety of prophylactic vs. on-demand treatment in hemophilia A or B subjects with inhibitors;Antunes;Journal of Thrombosis and Haemostasis: JTH,2013

2. Comparison of historic on-demand versus prospective on-demand and prophylaxis bleeding episodes in hemophilia A and B patients with inhibitors treated with FEIBA NF;Antunes;Haemophilia,2014

3. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors;Antunes;Haemophilia,2013

4. Health-related quality of life in hemophilia patients with inhibitors receiving prophylaxis with anti-inhibitor coagulant complex (AICC): results from the AICC prophylaxis study;Stasyshyn;Journal of Thrombosis and Haemostasis: JTH,2013

5. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study;Stasyshyn;Haemophilia,2014

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside;Current Issues in Molecular Biology;2024-05-23

2. Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India;Heliyon;2024-03

3. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27

4. Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis;Sao Paulo Medical Journal;2024

5. Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis;Expert Review of Hematology;2023-12-02